Is SLGL or SLXN more undervalued in 2026?

CirclFi compares Sol-Gel Technologies Ltd. (SLGL) and Silexion Therapeutics Corp (SLXN) using 13 institutional-grade valuation models. SLGL has a Quality of Company score of 2.1/10 while SLXN scores 5.3/10.

Which is a better buy — SLGL or SLXN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SLGL and SLXN valuations compare?

SLGL at $75.28 and SLXN at $0.43 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SLGL vs SLXN Valuation Comparison 2026 — Intrinsic Value Analysis

SLGL

Biotechnology

Sol-Gel Technologies Ltd.

Quality

2.1

out of 10

Value Trap

—

Price

$75.28

Last close

Models

10/13

Active

SLXN

Biotechnology

Silexion Therapeutics Corp

Quality

5.3

out of 10

Value Trap

SAFE

Price

$0.43

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	SLGL Fair Value	SLGL Upside	SLXN Fair Value	SLXN Upside
Bayesian DCF	Intrinsic	$19.96	-73.5%	$0.38	-10.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$4.09	-94.5%	$1.51	+252.8%
PWERM	Option-Based	$47.09	-36.2%	$1.30	+204.2%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SLGL vs SLXN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SLGL vs SLXN — Which Stock Is More Undervalued?

SLXN scores higher with a 5.3/10 quality rating vs SLGL's 2.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sol-Gel Technologies Ltd. (SLGL) and Silexion Therapeutics Corp (SLXN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SLGL currently trades at $75.28 with a QOC of 2.1/10, while SLXN trades at $0.43 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).